Business
InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019
InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business U...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen1{\nBORDER-TOP:0pt; BORDER-RIGHT:0pt; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt; BORDER-LEFT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, BC, May 8, 2019\n\n\n\nTSX:INOTCQX:IMLFF\n VANCOUVER, BC, May 8, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 (\"3Q19\"), on Wednesday, May 15, 2019.\nConference Call & Webcast:\nWednesday, May 15, 2019 at 10:00 AM Pacific Time, 1:00 PM Eastern Time\nToronto:\n+1.416.764.8688\nVancouver: \n+1.778.383.7413\nNorth America (Toll Free):\n+1.888.390.0546\nConference ID:\n17193517\nWebcast:  https://event.on24.com/wcc/r/1999675/955779A89027D040E64A5A3804E51DBE\n\n \n \n\n \n \nReplays, Available through May 22, 2019:\nToronto: \n+1.416.764.8677\nNorth America (Toll Free):\n+1.888.390.0541\nPlayback Passcode:\n193517 #\n \nThe Company's full financial statements and related MD&A for the three months ended March 31, 2019 will be available at www.sedar.com on May 15, 2019.\nAbout InMed:InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids, as well as a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs.  The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.  For...